Drug Trial Radar · NCT01138449
Efficacy of Newborn Vitamin A Supplementation Versus Placebo in Improving Child Survival (NeoVitA Trial)
Last checked: Nov 19, 2026Latest source record: Jun 1, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44,984
Actual
Start
Jun 2010
Primary completion
Jun 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Society for Applied StudiesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- World Health Organization
- First posted
- Jun 7, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 2 hours, up to 72 hours
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is a large randomized controlled trial to assess the efficacy and safety of neonatal vitamin A supplementation administered to neonates once orally either on the day of birth or in the next 2 days in improving infant survival in the first 6 months of life.
Conditions
- Neonatal Vitamin A Supplementation
Interventions
Vitamin ADrug
Retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil, orally as a single dose to neonates on the day of birth or in the next 2 days of birth keeping a minimum period of 2 hours between the birth and the dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Risk of deathTime frame: Period between receiving the intervention/placebo and six months of age
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Society for Applied Studies
New Delhi, National Capital Territory of Delhi, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.